OTC · Biotechnology

MedinCell S.A. (MDCLF) Stock

$34.39 +0.00% OTC: MDCLF Healthcare

MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments.

Valuation

MetricValue
Price$34.39
Market Cap$1.23B
P/E Ratio-27.12
P/B Ratio289.20
P/S Ratio45.41
EPS (TTM)$-0.87
52-Week High$34.39
52-Week Low$6.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE226.98%
ROA-28.95%
ROCE-29.20%
Gross Margin-125.00%
Operating Margin-130.65%
Net Margin-160.30%
Debt/Equity18.74
Current Ratio4.67

Annual Financials (USD)

Metric20222023202420252026
Revenue$4.0M$10.0M$9.0M$26.0M$20.0M
Operating Profit$-24.0M$-24.0M$-21.0M$-11.0M$-26.0M
Net Profit$-25.0M$-32.0M$-25.0M$-18.0M$-31.0M
EPS$-1.00$-1.27$-0.88$-0.63$-0.87
Op Margin-582.3%-241.6%-229.0%-42.4%-130.7%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$44.0M$29.0M$37.0M$90.0M$108.0M
Total Liabilities$58.0M$72.0M$78.0M$107.0M$105.0M
Cash$25.0M$6.0M$19.0M$59.0M$63.0M
Borrowings$47.0M$58.0M$59.0M$59.0M$57.0M

Latest News

Strathcona Resources Ltd. Reports Second Quarter 2026 Financial and Operating Results and Announces Quarterly Dividend PR Newswire · Aug 5, 2026 Disney Reaffirms Double-Digit Earnings Growth, Targets $9 Billion in Buybacks. Here’s What Investors Need to Know. Motley Fool · Aug 5, 2026 Meta Platforms Launches Muse Code AI Coding Tool Powered by Muse Spark 1.2 MT Newswires · Aug 5, 2026 Dow Jones Futures: Nvidia Lifts Dow, But Google, SpaceX Skid; Sandisk, Western Digital Lead Earnings Losers Late Investor's Business Daily · Aug 5, 2026 A Life360 Director Sold Stock at Exactly $60. Here's What Long-Term Investors Should Know Motley Fool · Aug 5, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-21.0M$-21.0M$-12.0M$19.0M$-25.0M
Investing Cash Flow$-2.0M$0$-2.0M$-15.0M$-13.0M
Financing Cash Flow$-1.0M$-5.0M$-3.0M$-2.0M$-3.0M
Net Cash Flow$-22.0M$-18.0M$13.0M$40.0M$4.0M
Free Cash Flow$-23.0M$-22.0M$-13.0M$18.0M$-27.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.56
EV / EBITDA-29.08
FCF Yield-2.92%
Quick Ratio4.67
Interest Coverage-3.87
Return 1Y392.98%
Return 3Y392.98%
Return 5Y—

Ownership

Insiders Held33.99%
Institutions Held31.65%
Institutions Float Held47.94%
Institutional HolderSharesReport Date
SmallCap World Fund Inc815,3442026-03-31
VANGUARD WHITEHALL FUNDS-Vanguard International Explorer Fund130,5692026-04-30
iShares Trust-iShares Core MSCI EAFE ETF115,5282026-06-30
iShares Trust-iShares MSCI EAFE Small-Cap ETF92,1862026-06-30
Nationwide Mutual Funds-Nationwide International Small Cap Fund39,2882026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About MedinCell S.A.

MedinCell S.A. is a pharmaceutical company dedicated to creating a diverse array of medical treatments. At the heart of its innovation is the BEPO platform, a unique technology designed for long-acting injectable drugs. This system utilizes specific proprietary copolymers alongside a compatible solvent to effectively dissolve or suspend active pharmaceutical compounds, ensuring their sustained release within the body. The company's clinical pipeline includes several notable projects: mdc-IRM, a subcutaneous injection intended for schizophrenia, which is currently undergoing late-stage (Phase III) clinical trials; mdc-CWM, an intra-articular injection formulated to alleviate pain and inflammation; and mdc-TJK, another subcutaneous injection also targeting schizophrenia, presently in preclinical evaluation. Furthermore, MedinCell's research efforts extend to numerous formulation candidates. These include subcutaneous injections like mdc-WWM for contraception, mdc-ANG for central nervous system conditions, mdc-ELK for depressive disorders, and mdc-GRT for applications in organ transplantation. The firm is also exploring perineural injection options such as mdc-CMV for anesthesia and pain management, and mdc-NVA, also for pain relief. MedinCell S.A. conducts its operations from its base in Jacou, France.

MedinCell S.A. is headquartered in FR.

MedinCell S.A. (MDCLF) stock trades at $34.39 with a market capitalization of $1.23B. The stock is valued at a price-to-earnings (P/E) ratio of -27.12, price-to-book of 289.20, price-to-sales of 45.41. Over the past 52 weeks the stock has ranged between $6.98 and $34.39, and currently trades at its 52-week high.

On profitability, MedinCell S.A. generates a return on equity (ROE) of 226.98% — well above the market average, a sign of a high-quality business, return on capital employed of -29.20%, an operating margin of -130.65%, a net profit margin of -160.30%.

Official website: www.medincell.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides